Skip to content
← Full study record

NCT02454972 · MORE INFO

Limitations, agreements, and source contact

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors · Source last updated 2023-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@pharmamar.com
organization
Pharma Mar S.A.
phone
0034 91846 60 00
title
Clinical Development, Department of PharmaMar´s Oncology., Business Unit.
Complete source fields
certain Agreement
other Details
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@pharmamar.com
organization
Pharma Mar S.A.
phone
0034 91846 60 00
title
Clinical Development, Department of PharmaMar´s Oncology., Business Unit.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice